Original Research

Published on 21 Nov 2023

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study

in Pharmacoepidemiology

Tengfei Yuan
Faping Li
Yuchuan Hou
Hui Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1266890

2,370 views
3 citations

Original Research

Published on 16 Nov 2023

Associated adverse health outcomes of polypharmacy and potentially inappropriate medications in community-dwelling older adults with diabetes

in Pharmacoepidemiology

Lvliang Lu
Shuang Wang
Jiaqi Chen
Yujie Yang
Kai Wang
Jing Zheng
Pi Guo
Yunpeng Cai
Qingying Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1284287

1,981 views
3 citations

Original Research

Published on 16 Nov 2023

Antidepressants use during pregnancy and child psychomotor, cognitive and language development at 2 years of age—Results from the 3D Cohort Study

in Pharmacoepidemiology

Noémie Tanguay
Nadia Abdelouahab
Marie-Noelle Simard
Jean R. Séguin
Isabelle Marc
Catherine M. Herba
Andrea A. N. MacLeod
Yohann Courtemanche
William D. Fraser
Gina Muckle

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1252251

2,815 views
2 citations

Original Research

Published on 14 Nov 2023

Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)

in Pharmacoepidemiology

Victor Pera
Guy G. Brusselle
Sebastian Riemann
Jan A. Kors
Erik M. Van Mulligen
Rowan Parry
Marcel de Wilde
Peter R. Rijnbeek
Katia M. C. Verhamme

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1276340

4,328 views
4 citations

Original Research

Published on 10 Nov 2023

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database

in Pharmacoepidemiology

Wensheng Liu
Qiong Du
Zihan Guo
Xuan Ye
Jiyong Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1283247

4,480 views
7 citations

Original Research

Published on 09 Nov 2023

The influence of general practitioner and patient sex on the treatment of major depression

in Pharmacoepidemiology

Elisabeth Jufresa-Blanch
Neus Carrilero
Anna García-Altés

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1274774

1,732 views

Original Research

Published on 09 Nov 2023

Gender differences in spontaneous adverse event reports associated with zolpidem in South Korea, 2015–2019

in Pharmacoepidemiology

Kyung-In Joung

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1256245

1,670 views
2 citations

Original Research

Published on 07 Nov 2023

Antihypertensive medications and risk of colorectal cancer in British Columbia

in Pharmacoepidemiology

Jia Qi
Parveen Bhatti
John J. Spinelli
Rachel A. Murphy

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1301423

1,311 views

Original Research

Published on 06 Nov 2023

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis

in Pharmacoepidemiology

Annamaria Mascolo
Concetta Rafaniello
Gabriella di Mauro
Donatella Ruggiero
Maria Rosaria Campitiello
Maria Donniacuo
Pasquale Maria Berrino
Francesco Rossi
Giuseppe Paolisso
Annalisa Capuano

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1245642

2,202 views
2 citations

Brief Research Report

Published on 03 Nov 2023

Statutory health insurance-covered pre-exposure prophylaxis in Germany: changing trends in nationwide tenofovir disoproxil/emtricitabine prescriptions during the COVID-19 pandemic

in Pharmacoepidemiology

Henrieke Prins
Achim Dörre
Daniel Schmidt

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1241310

3,126 views
1 citation

Original Research

Published on 01 Nov 2023

Associations between COVID-19 outcomes and asthmatic patients with inhaled corticosteroid

in Pharmacoepidemiology

Su-Boon Yong
Shuo-Yan Gau
Chia-Jung Li
Chih-Wei Tseng
Shiow-Ing Wang
James Cheng-Chung Wei

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1204297

2,204 views
7 citations

Original Research

Published on 31 Oct 2023

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

in Pharmacoepidemiology

Yankun Liang
Lin Ma
Yuting Wang
Jingping Zheng
Ling Su
Jun Lyu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1253799

3,614 views
3 citations

Original Research

Published on 30 Oct 2023

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study

in Pharmacoepidemiology

Yun-Kyoung Song
Gaeun Lee
Jinseub Hwang
Ji-Won Kim
Jin-Won Kwon

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1165711

3,366 views
4 citations

Original Research

Published on 30 Oct 2023

Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study

in Pharmacoepidemiology

Yan Li
Zhengyuan Hu
Yufei Guo
Zheng Zhao
Kunpeng Li
Xiuru Wang
Jie Zhang
Dongfeng Liang
Jianglin Zhang
Xiaoyue Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1266915

1,446 views
2 citations

Original Research

Published on 26 Oct 2023

Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade

in Pharmacoepidemiology

Kassem Sharif
Mahmud Omar
Adi Lahat
Yonatan Shneor Patt
Howard Amital
Ghanem Zoabi
Nicola Luigi Bragazzi
Abdulla Watad

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1271309

2,194 views
2 citations

Original Research

Published on 26 Oct 2023

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?

in Pharmacoepidemiology

Zhiwei Cui
Feiyan Cheng
Lihui Wang
Fan Zou
Rumeng Pan
Yuhan Tian
Xiyuan Zhang
Jing She
Yidan Zhang
Xinyuan Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1259908

4,069 views
6 citations

Navigation group

Articles

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study

Associated adverse health outcomes of polypharmacy and potentially inappropriate medications in community-dwelling older adults with diabetes

Antidepressants use during pregnancy and child psychomotor, cognitive and language development at 2 years of age—Results from the 3D Cohort Study

Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database

The influence of general practitioner and patient sex on the treatment of major depression

Gender differences in spontaneous adverse event reports associated with zolpidem in South Korea, 2015–2019

Antihypertensive medications and risk of colorectal cancer in British Columbia

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis

Statutory health insurance-covered pre-exposure prophylaxis in Germany: changing trends in nationwide tenofovir disoproxil/emtricitabine prescriptions during the COVID-19 pandemic

Associations between COVID-19 outcomes and asthmatic patients with inhaled corticosteroid

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study

Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study

Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?